AbbVie Resolves Lawsuit with Generic Upadacitinib Manufacturers.
ByAinvest
Friday, Sep 12, 2025 6:49 am ET1min read
ABBV--
The agreement, which includes license terms, prevents generic entry for Upadacitinib tablets until April 2037 in the United States. Pediatric exclusivity could further extend the market protection under the agreement [1]. This settlement is a strategic move for AbbVie to maintain its market share and revenue stream from Upadacitinib, a key drug in its portfolio.
The settlement comes amid strong sales performance for Upadacitinib. In the second quarter of 2025, Rinvoq (Upadacitinib) sales reached $2.03 billion, an increase of 41.8% year over year (+41.2% on an operational basis) [1]. The FDA approved Upadacitinib for treating giant cell arteritis in April, further expanding its indications [1].
While the settlement does not impact AbbVie's net sales, which are primarily generated in the United States and other developed markets, it does provide a buffer against generic competition. This allows AbbVie to continue generating revenue from Upadacitinib while potentially securing a more stable pricing environment.
Investors should monitor the ongoing legal battle between Ionis Pharmaceuticals (IONS) and Arrowhead Pharmaceuticals (ARWR), which could have broader implications for the pharmaceutical industry [2]. However, the immediate focus remains on AbbVie's strategic move to secure market protection for Upadacitinib.
AbbVie Inc. has settled a lawsuit with generic producers of Upadacitinib, a drug intended for treating rheumatoid arthritis, psoriasis, and other conditions. The settlement resolves patent infringement claims and allows generic versions of the drug to enter the market. AbbVie will receive royalties on sales of generic Upadacitinib. The settlement will not impact AbbVie's net sales, which are primarily generated in the United States and other developed markets.
AbbVie Inc. (ABBV) has reached a settlement with generic producers of Upadacitinib, a drug intended for treating rheumatoid arthritis, psoriasis, and other conditions. The settlement resolves patent infringement claims and allows generic versions of the drug to enter the market, with AbbVie receiving royalties on sales of generic Upadacitinib [1].The agreement, which includes license terms, prevents generic entry for Upadacitinib tablets until April 2037 in the United States. Pediatric exclusivity could further extend the market protection under the agreement [1]. This settlement is a strategic move for AbbVie to maintain its market share and revenue stream from Upadacitinib, a key drug in its portfolio.
The settlement comes amid strong sales performance for Upadacitinib. In the second quarter of 2025, Rinvoq (Upadacitinib) sales reached $2.03 billion, an increase of 41.8% year over year (+41.2% on an operational basis) [1]. The FDA approved Upadacitinib for treating giant cell arteritis in April, further expanding its indications [1].
While the settlement does not impact AbbVie's net sales, which are primarily generated in the United States and other developed markets, it does provide a buffer against generic competition. This allows AbbVie to continue generating revenue from Upadacitinib while potentially securing a more stable pricing environment.
Investors should monitor the ongoing legal battle between Ionis Pharmaceuticals (IONS) and Arrowhead Pharmaceuticals (ARWR), which could have broader implications for the pharmaceutical industry [2]. However, the immediate focus remains on AbbVie's strategic move to secure market protection for Upadacitinib.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet